Education
About Us
Working with TipRanks
Follow Us
Kura Oncology (KURA)
NASDAQ:KURA
KURA Stock Chart & Stats
$11.97
-$0.35(-4.35%)
At close: 4:00 PM EST
$11.97
-$0.35(-4.35%)
Day’s Range― - ―
52-Week Range$5.41 - $12.49
Previous CloseN/A
Volume631.17K
Average Volume (3M)2.03M
Market Cap
$968.50M
Enterprise Value$245.46M
Total Cash (Recent Filing)$549.66M
Total Debt (Recent Filing)$19.47M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Mar 03, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding87,017,520
10 Day Avg. Volume1,339,530
30 Day Avg. Volume2,032,456
Financial Highlights & Ratios
PEG Ratio1.50
Price to Book (P/B)1.81
Price to Sales (P/S)13.93
P/FCF Ratio5.61
Enterprise Value/Market Cap0.25
Enterprise Value/Revenue2.36
Enterprise Value/Gross Profit2.43
Enterprise Value/Ebitda-1.11
Forecast
1Y Price Target
$29.00Price Target Upside142.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.51
Revenue Forecast (FY)$130.15M
Bulls Say, Bears Say
Bulls Say
Financial And Commercial ReadinessCash reserves, along with expected funding, are believed to support operations through 2027 and ziftomenib development through the KOMET-017 topline.
Safety And Efficacy AdvantageKOMZIFTI’s competitive advantage relies on strong efficacy signal, simplicity, favorable safety, and compatibility, which could support positioning of KOMZIFTI as the menin inhibitor of choice.
Therapy Approval And Market PositionKOMZIFTI is now available to U.S. prescribers as the first and only, once daily, targeted therapy approved for r/r NPM1-m AML.
Bears Say
Investor SkepticismThere is a short interest of 16.7% in Kura Oncology's stock, indicating some skepticism among investors.
Pricing ConcernsDespite its benefits, Komzii's wholesale acquisition cost is higher than expected.
Safety ConcernsThe label includes a boxed warning for differentiation syndrome, which occurred in 26% of patients and was fatal in 2%.
Kura Oncology News
KURA FAQ
What was Kura Oncology’s price range in the past 12 months?
Kura Oncology lowest stock price was $5.41 and its highest was $12.49 in the past 12 months.
What is Kura Oncology’s market cap?
Kura Oncology’s market cap is $968.50M.
When is Kura Oncology’s upcoming earnings report date?
Kura Oncology’s upcoming earnings report date is Mar 03, 2026 which is in 88 days.
How were Kura Oncology’s earnings last quarter?
Kura Oncology released its earnings results on Nov 04, 2025. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.73 by -$0.12.
Is Kura Oncology overvalued?
According to Wall Street analysts Kura Oncology’s price is currently Undervalued.
Does Kura Oncology pay dividends?
Kura Oncology does not currently pay dividends.
What is Kura Oncology’s EPS estimate?
Kura Oncology’s EPS estimate is -0.25.
How many shares outstanding does Kura Oncology have?
Kura Oncology has 87,017,520 shares outstanding.
What happened to Kura Oncology’s price movement after its last earnings report?
Kura Oncology reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.73. Following the earnings report the stock price went up 1.945%.
Which hedge fund is a major shareholder of Kura Oncology?
Currently, no hedge funds are holding shares in KURA
Kura Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.00 (142.27% Upside)
$29.00 (142.27% Upside)
Blogger Sentiment
Bullish
KURA Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 162.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $786.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 13.9%
Last 30 Days ▲ 13.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.16%
12-Months-Change
Fundamentals
Return on Equity
-65.10%
Trailing 12-Months
Asset Growth
35.62%
Trailing 12-Months
Company Description
Kura Oncology
Kura Oncology, Inc. (KURA) is a biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of cancer. The company is involved in the research and development of small molecule drug candidates primarily targeting genetically defined patient populations. Its core products include tipifarnib, ziftomenib, and KO-2806, which are in various stages of clinical trials for different types of cancer, such as acute myeloid leukemia and other solid tumors.
KURA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong focus on advancing clinical development, particularly for ziftomenib, with significant progress in trials and preparations for a potential FDA approval. Despite financial challenges, the company's strategic partnerships and clinical advancements position it well for future growth. The sentiment is positive, driven by strong clinical and commercial progress.View all KURA earnings summariesKURA Stock 12 Month Forecast
Average Price Target
$29.00
▲(142.27% Upside)
Technical Analysis
Oruka Therapeutics
―
Phathom Pharmaceuticals
―
Keros Therapeutics
―
Tyra Bioscience
―
Septerna, Inc.
―
Ownership Overview
2.28% Insiders
11.66% Mutual Funds
35.13% Other Institutional Investors
36.77% Public Companies and
Individual Investors